Cytokine signaling converging on

IL11 co-culture model cytokine disease modeling human pluripotent stem cells interstitial lung disease organoids secretome

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 20 12 2022
accepted: 23 03 2023
medline: 5 6 2023
pubmed: 2 6 2023
entrez: 2 6 2023
Statut: epublish

Résumé

Interstitial lung disease (ILD) is a heterogenous group of lung disorders where destruction and incomplete regeneration of the lung parenchyma often results in persistent architectural distortion of the pulmonary scaffold. Continuous mesenchyme-centered, disease-relevant signaling likely initiates and perpetuates the fibrotic remodeling process, specifically targeting the epithelial cell compartment, thereby destroying the gas exchange area. With the aim of identifying functional mediators of the lung mesenchymal-epithelial crosstalk with potential as new targets for therapeutic strategies, we developed a 3D organoid co-culture model based on human induced pluripotent stem cell-derived alveolar epithelial type 2 cells that form alveolar organoids in presence of lung fibroblasts from fibrotic-ILD patients, in our study referring to cases of pulmonary fibrosis, as well as control cell line (IMR-90). While organoid formation capacity and size was comparable in the presence of fibrotic-ILD or control lung fibroblasts, metabolic activity was significantly increased in fibrotic-ILD co-cultures. Alveolar organoids cultured with fibrotic-ILD fibroblasts further demonstrated reduced stem cell function as reflected by reduced Surfactant Protein C gene expression together with an aberrant basaloid-prone differentiation program indicated by elevated Cadherin 2, Bone Morphogenic Protein 4 and Vimentin transcription. To screen for key mediators of the misguided mesenchymal-to-epithelial crosstalk with a focus on disease-relevant inflammatory processes, we used mass spectrometry and characterized the secretome of end stage fibrotic-ILD lung fibroblasts in comparison to non-chronic lung disease (CLD) patient fibroblasts. Out of the over 2000 proteins detected by this experimental approach, 47 proteins were differentially abundant comparing fibrotic-ILD and non-CLD fibroblast secretome. The fibrotic-ILD secretome profile was dominated by chemokines, including CXCL1, CXCL3, and CXCL8, interfering with growth factor signaling orchestrated by Interleukin 11 (IL11), steering fibrogenic cell-cell communication, and proteins regulating extracellular matrix remodeling including epithelial-to-mesenchymal transition. When in turn treating alveolar organoids with IL11, we recapitulated the co-culture results obtained with primary fibrotic-ILD fibroblasts including changes in metabolic activity. We identified mediators likely contributing to the disease-perpetuating mesenchymal-to-epithelial crosstalk in ILD. In our alveolar organoid co-cultures, we were able to highlight the importance of fibroblast-initiated aberrant epithelial differentiation and confirmed IL11 as a key player in fibrotic-ILD pathogenesis by unbiased fibroblast secretome analysis.

Identifiants

pubmed: 37266432
doi: 10.3389/fimmu.2023.1128239
pmc: PMC10230276
doi:

Substances chimiques

Interleukin-11 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1128239

Informations de copyright

Copyright © 2023 Kastlmeier, Gonzalez-Rodriguez, Cabanis, Guenther, König, Han, Hauck, See, Asgharpour, Bukas, Burgstaller, Piraud, Lehmann, Hatz, Behr, Stoeger, Hilgendorff and Voss.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Pediatr Allergy Immunol Pulmonol. 2010 Mar;23(1):9-14
pubmed: 22087431
J Proteome Res. 2014 Mar 7;13(3):1234-47
pubmed: 24512137
Annu Rev Med. 2020 Jan 27;71:263-276
pubmed: 31986085
Cells. 2022 Jun 02;11(11):
pubmed: 35681516
J Clin Invest. 2020 Oct 1;130(10):5088-5099
pubmed: 32870817
Am J Physiol Lung Cell Mol Physiol. 2016 Sep 1;311(3):L590-601
pubmed: 27474089
ERJ Open Res. 2023 May 22;9(3):
pubmed: 37228276
IEEE Trans Pattern Anal Mach Intell. 1986 Jun;8(6):679-98
pubmed: 21869365
J Clin Invest. 2007 Mar;117(3):549-56
pubmed: 17332882
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
Respir Res. 2019 Sep 6;20(1):204
pubmed: 31492143
Mol Cell Proteomics. 2016 Feb;15(2):462-80
pubmed: 26324419
Nat Protoc. 2019 Dec;14(12):3303-3332
pubmed: 31732721
Int J Mol Sci. 2022 Dec 10;23(24):
pubmed: 36555307
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 28432134
J Clin Invest. 2017 Jun 1;127(6):2277-2294
pubmed: 28463226
J Clin Invest. 2009 Jun;119(6):1417-9
pubmed: 19487817
Cell Rep. 2019 Jun 18;27(12):3709-3723.e5
pubmed: 31216486
Sci Transl Med. 2019 Sep 25;11(511):
pubmed: 31554736
Cell Stem Cell. 2017 Oct 5;21(4):472-488.e10
pubmed: 28965766
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
J Biol Methods. 2016 Jul 24;3(3):e49
pubmed: 31453214
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cells. 2022 Jun 28;11(13):
pubmed: 35805139
Nat Commun. 2020 Jul 16;11(1):3559
pubmed: 32678092
Growth Factors. 2008 Feb;26(1):12-22
pubmed: 18365875
Am J Respir Cell Mol Biol. 2021 Oct;65(4):345-346
pubmed: 34153206
Sci Adv. 2020 Jul 08;6(28):eaba1972
pubmed: 32832598
Exp Mol Med. 2020 Dec;52(12):1871-1878
pubmed: 33262481
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L682-L696
pubmed: 29952218
Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L566-77
pubmed: 12618418
Stem Cell Res Ther. 2021 Jan 30;12(1):95
pubmed: 33516265
Nat Cell Biol. 2022 Jan;24(1):10-23
pubmed: 34969962
Sci Adv. 2020 Jul 08;6(28):eaba1983
pubmed: 32832599
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
J Biol Chem. 2021 Sep;297(3):101096
pubmed: 34418430
ERJ Open Res. 2017 Mar 22;3(1):
pubmed: 28435843
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Biomaterials. 2018 Feb;155:124-134
pubmed: 29175081
Nucleic Acids Res. 2020 Jan 8;48(D1):D1145-D1152
pubmed: 31686107
Development. 2018 Aug 15;145(16):
pubmed: 30111617
Genes Dis. 2019 Oct 03;7(2):172-184
pubmed: 32215287

Auteurs

Miriam T Kastlmeier (MT)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Erika Gonzalez-Rodriguez (E)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Phoebe Cabanis (P)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Eva M Guenther (EM)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Ann-Christine König (AC)

Metabolomics and Proteomics Core (MPC), Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Munich, Germany.

Lianyong Han (L)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Stefanie M Hauck (SM)

Metabolomics and Proteomics Core (MPC), Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Munich, Germany.

Fenja See (F)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Sara Asgharpour (S)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Christina Bukas (C)

Helmholtz AI, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Munich, Germany.

Gerald Burgstaller (G)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Marie Piraud (M)

Helmholtz AI, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Munich, Germany.

Mareike Lehmann (M)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.
Institute for Lung Research, Philipps-University Marburg, Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL), Marburg, Germany.

Rudolf A Hatz (RA)

Klinik für Thoraxchirurgie, Asklepios Fachkliniken München-Gauting, Thoraxchirurgie, Munich, Germany.

Jürgen Behr (J)

Department of Medicine V, University Hospital, Ludwig-Maximilians University Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany.

Tobias Stoeger (T)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Anne Hilgendorff (A)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.
Dr. von Haunersche Children's Hospital, Hospital of the Ludwig-Maximilians University, Member of the German Lung Research Center (DZL), Munich, Germany.

Carola Voss (C)

Institute of Lung Health and Immunity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Comprehensive Pneumology Center Munich with the CPC-M bioArchive, Member of the German Center of Lung Research (DZL), Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH